C-Bridge Capital Leads $100M Round In Chinese Drug Start-Up Ascletis

Login to View

C-Bridge Capital, a US$700 million-under-management healthcare private equity fund in China, has led a US$100 million new funding round in Chinese pharmaceutical start-up Ascletis, according to Chinese media reports.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in